Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus

Journal of Investigative Dermatology

Volumn 133, Issue 4, 2013, Pages 1034-1042

  Kaufmann, Johanna K ^a,b   Bossow, Sascha ^a   Grossardt, Christian ^a   Sawall, Stefanie ^a   Kupsch, Jörg ^c   Erbs, Philippe ^d   Hassel, Jessica C ^b   Von Kalle, Christof ^a   Enk, Alexander H ^b   Nettelbeck, Dirk M ^a,b   Ungerechts, Guy ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

^d TRANSGENE S A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN; MELANOMA ANTIGEN; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MEASLES VIRUS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL;

EID: 84875217712     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.459     Document Type: Article

References (36)

1. Boisgerault N, Tangy F, Gregoire M (2010) New perspectives in cancer virotherapy: bringing the immune system into play. Immunotherapy 2:185-99
2. Bossow S, Grossardt C, Temme A et al. (2011) Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther 18:598-608
3. Cameron F, Whiteside G, Perry C (2011) Ipilimumab: first global approval. Drugs 71:1093-4
4. Campoli M, Ferrone S, Wang X (2010) Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res 109:73-121
5. Chalikonda S, Kivlen MH, O'Malley ME et al. (2008) Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther 15:115-25
6. Conrad C, Miller CR, Ji Y et al. (2005) Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 12:284-94
7. Dias JD, Liikanen I, Guse K et al. (2010) Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res 16:2540-9
8. Donnelly OG, Errington-Mais F, Steele L et al. (2011) Measles virus causes immunogenic cell death in human melanoma. Gene Ther doi:10.1038/gt.2011. 205
9. Erbs P, Regulier E, Kintz J et al. (2000) In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 60:3813-22
10. Foloppe J, Kintz J, Futin N et al. (2008) Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 15:1361-71
11. Fuerer C, Iggo R (2004) 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene. Gene Ther 11:142-51
12. Galanis E (2010) Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther 88:620-5
13. Heakal Y, Kester M, Savage S (2011) Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother 45:1399-405
14. Johnson AJ, Ardiani A, Sanchez-Bonilla M et al. (2011) Comparative analysis of enzyme and pathway engineering strategies for 5FC-mediated suicide gene therapy applications. Cancer Gene Ther 18:533-42
15. Kang N, Hamilton S, Odili J et al. (2000) In vivo targeting of malignant melanoma by 125Iodine- and 99mTechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen. Clin Cancer Res 6:4921-31
16. Kaufmann JK, Nettelbeck DM (2012) Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond. Trends Mol Med 18:365-76
17. Li H, Peng KW, Dingli D et al. (2010) Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 17:550-8
18. Maciag PC, Seavey MM, Pan ZK et al. (2008) Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 68:8066-75
19. MacKie RM, Hauschild A, Eggermont AM (2009) Epidemiology of invasive cutaneous melanoma. Ann Oncol 20(Suppl 6):vi1-7
20. Martin A, Staeheli P, Schneider U (2006) RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. J Virol 80:5708-15
21. Nakamura H, Mullen JT, Chandrasekhar S et al. (2001) Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 61:5447-2
22. Nakamura T, Peng KW, Harvey M et al. (2005) Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23:209-14
23. Nakamura T, Peng KW, Vongpunsawad S et al. (2004) Antibody-targeted cell fusion. Nat Biotechnol 22:331-6
24. Nettelbeck DM, Rivera AA, Kupsch J et al. (2004) Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int J Cancer 108:136-45
25. Portsmouth D, Hlavaty J, Renner M (2007) Suicide genes for cancer therapy. Mol Aspects Med 28:4-41
26. Quirin C, Rohmer S, Fernandez-Ulibarri I et al. (2011) Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy. Hum Gene Ther 22:389-404
27. Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30:658-70
28. Schlingemann RO, Rietveld FJ, de Waal RM et al. (1990) Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 136:1393-405
29. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
30. Ungerechts G, Frenzke ME, Yaiw KC et al. (2010) Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther 17:1506-516
31. Ungerechts G, Springfeld C, Frenzke ME et al. (2007a) Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 67:10939-47
32. Ungerechts G, Springfeld C, Frenzke ME et al. (2007b) An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 15:1991-7
33. Vongpunsawad S, Oezgun N, Braun W et al. (2004) Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46- induced fusion and their localization on a new hemagglutinin structural model. J Virol 78:302-13
34. Yamada S, Kuroda T, Fuchs BC et al. (2012) Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation. Cancer Gene Ther 19:160-70
35. Zaoui K, Bossow S, Grossardt C et al. (2012) Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. Cancer Gene Ther 19:181-91
36. Zimmermann M, Weiland T, Bitzer M et al. (2012) Preclinical testing of virotherapeutics for primary and secondary tumors of the liver. Methods Mol Biol 806:121-36